67915-31-5 Categories: , ,
  • #LGM Pharma is a Terconazole CAS# 67915-31-5 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 67915-31-5
  • AHFC code: 84:04.08.08
  • Synonyms: Triaconazole
  • ATC Code: G01AG02
  • Chemical Formula: C181H291N55O51S2
  • Molecular Weight: 532.462
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00251 (APRD00659)
  • SMILES: CC(C)N1CCN(CC1)C1=CC=C(OC[C,H]2CO[C,,](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
  • PubChem: 441383
  • IUPAC: 1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(propan-2-yl)piperazine

Additional Details

For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.
Terconazole is a triazole antifungal agent available for intravaginal use. It is structurally related to imidazole-derivative antifungal agents, although terconazole and other triazoles have 3 nitrogens in the azole ring. By inhibiting the 14-alpha-demethylase (lanosterol 14-alpha-demethylase), Terconazole inhibits ergosterol synthesis. Depletion of ergosterol in fungal membrane disrupts the structure and many functions of fungal membrane leading to inhibition of fungal growth.
Mode of Action:
Terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. Terconazole and other triazole antifungal agents inhibit cytochrome P450 14-alpha-demethylase in susceptible fungi, which leads to the accumulation of lanosterol and other methylated sterols and a decrease in ergosterol concentration. Depletion of ergosterol in the membrane disrupts the structure and function of the fungal cell leading to a decrease or inhibition of fungal growth.
Systemically absorbed drug appears to be rapidly and extensively metabolized. Terconazole primarily undergoes oxidatative N- and O-dealkylation, dioxolane ring cleavage, and conjugation.
The oral LD50 values were found to be 1741 and 849 mg/kg for the male and female in rat.
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials


Related YouTube Videos